Abstract CT264: Mutant KRAS peptide vaccine combined with ipilimumab/nivolumab in advanced mismatch repair proficient/microsatellite stable (MMRp/MSS) colorectal cancer: Preliminary analysis from a phase I study
Hejia Wang(Bloomberg (United States)), Neeha Zaidi(Johns Hopkins University), Michael J. Pishvaian(The University of Texas MD Anderson Cancer Center), Amanda L. Huff(Johns Hopkins University), Marina Baretti(Sidney Kimmel Comprehensive Cancer Center), Christopher J. Thoburn(Johns Hopkins University), Daniel A. Laheru(Bloomberg (United States)), Eric S. Christenson(Johns Hopkins University), Elizabeth M. Jaffee(Bloomberg (United States)), Saurav D. Haldar(Broad Institute), Jiayun Lu(Bloomberg (United States)), Maureen Berg(Johns Hopkins University), Hao Wang(Johns Hopkins University), Julie M. Nauroth(Sidney Kimmel Comprehensive Cancer Center), Mark Yarchoan(Sidney Kimmel Comprehensive Cancer Center), Katherine M. Bever(Sidney Kimmel Comprehensive Cancer Center), Valerie Lee(Johns Hopkins University), Nilofer S. Azad(Sidney Kimmel Comprehensive Cancer Center), Dung T. Le(Johns Hopkins University), Amy Thomas, Jennifer N. Durham(Sidney Kimmel Comprehensive Cancer Center)
Cited by 3
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k